drugset / Trial / NCT07101328
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Timeline
- Start
- 2026-05-28
- Primary completion
- 2027-04
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4152199 | Unknown | — | Intravenous |